Table 2.
Characteristics of participants in SGLT2 inhibitor trials that specifically recruited patients with CKD
| Characteristics | CREDENCE46 | DAPA-CKD8 | SCORED37 | EMPA-KIDNEY58 |
|---|---|---|---|---|
| Number of participants | 4401 | 4304 | 10584 | 6609 |
| Mean age (yr) | 63 | 61.8 | 69 | 63.8 |
| Female (%) | 1494 (33.9) | 1425 (33.1) | 4754 (44.9) | 2192 (33) |
| UACR (mg/g) Median (IQR) |
927 (463–1833) | 949.3 | 74 (17–481) | 412 (94–1190) |
| eGFR (ml/min per 1.73 m2) mean (SD) |
56.2 (18.2) | 43.1 (12.4) | 44.5 | 37.5 (14.8) |
| eGFR categories (%) | ||||
| ≥45 ml/min per 1.73 m2 | 3035 (69) | 1782 (41.4) | 5116 (48.3) | 1424 (22) |
| ≥30–44 ml/min per 1.73 m2 | 1191 (27.1) | 1898 (44.1) | 4655 (43.9) | 2905 (44) |
| <30 ml/min per 1.73 m2 | 174 (3.9) | 624 (14.5) | 813 (7.8) | 2280 (34) |
| Prior DM (%) | 4401 (100) | 2888 (67.1) | 10,584 (100) | 3039 (46) |
| Baseline RAAS inhibitor (%) | 4395 (99) | 4224 (98.1) | 9365 (88.5) | 5613 (84.9) |
| Primary kidney disease (%) | ||||
| Diabetic kidney disease | 4401 (100) | 2510 (58.3) | 10,584 (100) | 2057 (31) |
| Ischemic/hypertensive nephropathy | 687 (16) | 1445 (22) | ||
| Glomerular disease | 695 (16.1) | 1669 (25) | ||
| IgA nephropathy | 270 (6.3) | 817 (12) | ||
| Focal segmental glomerulosclerosis | 115 (2.7) | 195 (3.0) | ||
| Membranous nephropathy | 43 (1.0) | 96 (1.0) | ||
| Minimal change disease | 11 (0.3) | 14 (<1) | ||
| Other glomerular disease | 256 (5.9) | 547 (8.0) | ||
| Unknown | 214 (5) | 630 (10) | ||
| Other | 198 (4.6) | 808 (12) | ||
CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate (CKD-EPI); IQR, interquartile range; RAAS, renin-angiotensin-aldosterone inhibitor; UACR, urine microalbumin-to-creatinine ratio.